Oral Cancer & Oral Potentially Malignant Disorders: What Providers Need to Know

  • Thursday 1/26/2023
  • Time: 1:00 - 4:00 pm
  • Course Code: 135TL
  • Cost: $125
  • Room Location: BCEC Room 105
  • Credits: 3 CE Hours
Glenn Hanna, MD joined the faculty of the Center for Head and Neck Oncology in 2017 at Dana-Farber Cancer Institute. Dr. Hanna's clinical and translational research efforts are focused on both molecular and immunologic biomarker discovery to foster precision medicine approaches to treat head and neck cancers and improve patient outcomes.
Reshma Menon, BDS is faculty of the department of oral medicine, infection and immunity at Harvard School of Dental Medicine and a diplomate of the American Board of Oral and Maxillofacial Pathology. She runs a clinical pathology practice and directs the medically complex patient program. Additionally, she teaches in and directs many predoctoral and graduate courses, holds several leadership positions including being the chair of the educational quality improvement committee and conducts research in dental education, oral medicine and maxillofacial pathology.
Eleni Rettig, MD is a head and neck surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute at Harvard Medical School. She specializes in the surgical treatment of head and neck cancers, salivary gland tumors, cutaneous malignancies, and thyroid and parathyroid tumors; transoral robotic surgery for oropharynx cancers; and microvascular reconstruction of the head and neck. As part of the Dana-Farber Head and Neck Cancer Treatment Center, she works within a multidisciplinary team to provide comprehensive cancer care. Dr. Rettig’s research interests include human papillomavirus-positive oropharynx cancer, head and neck cancer epidemiology, and health-related quality of life among head and neck cancer patients. Dr. Rettig is a graduate of Yale University and received her medical degree from Baylor College of Medicine. She completed residency training in Otolaryngology – Head and Neck Surgery at Johns Hopkins followed by a fellowship in Advanced Head and Neck Oncologic and Reconstructive Surgery at the Mayo Clinic in Rochester, MN. She is board certified by the American Board of Otolaryngology-Head and Neck Surgery.
Rosh Sethi, MD
Herve Sroussi, DMD, PhD is an associate professor in the Department of Oral Medicine and Diagnostic Sciences at the College of Dentistry at the University of Illinois in Chicago. He is the chief of Oral Medicine and the director for Graduate Studies in the Oral Sciences Program. He is a diplomate of the American Academy of Oral Medicine.
Nathaniel Treister, DMD is an associate surgeon and chief of the division of Oral Medicine and Dentistry at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, and assistant professor of Oral Medicine in the Department of Oral Medicine, Infection, and Immunity at Harvard School of Dental Medicine. He is a diplomate of the American Board or Oral Medicine.
Piamkamon Vacharotayangul, DDS, PhD graduated from Mahidol University, Bangkok, Thailand in 1997. That same year she joined the newly established faculty of dentistry at Srinakhariwirot University before pursuing a PhD and advanced clinical training in Oral Medicine at UCSF in 1999. After graduation in 2006, she returned to Srinakharinwirot University to lead the Division of Oral Medicine for 8 years. She continued as a special instructor in oral medicine for many dental faculties in Thailand until 2018, when she took on the translation of Atlas of Oral Diseases by Professor Isaac van der Waal from English into Thai. American Oral Medicine Board certified in 2019, she accepted her current role as Associate Surgeon and Director of Advanced Graduate Education Program at Brigham and Women’s Hospital Division of Oral Medicine and Dentistry in 2020.

This course will provide an in-depth contemporary overview of oral cancer and oral potentially malignant disorders (OPMDs), from epidemiology, risk factors, diagnosis and work-up, to multidisciplinary and multimodality management. Topics include updates on the most recent advances in diagnostics, treatment and follow-up regimens for oral potentially malignant disorders and oral cancers, HPV and oropharyngeal cancer, and indications for use of novel therapies including immune checkpoint inhibitors. The role of the dentist and the oral health care team will be emphasized throughout, including guidelines for dental and oral health management from diagnosis through survivorship. The course faculty are members of the Dana-Farber/Brigham and Women’s Hospital Head and Neck Oncology program where they work together closely as part of a multidisciplinary team.

After this course attendees will be able to:
  • Discuss the epidemiology of oral cancer and its associated risk factors
  • Understand the role of HPV in oropharyngeal cancer pathogenesis 
  • Review the clinical features, diagnosis, and management of OPMDs
  • Explain how oral cancer is diagnosed, and how a newly diagnosed patient is worked-up for cancer staging and treatment planning
  • Recognize that management of oral cancer involves multiple treatment modalities requiring a well-coordinated multidisciplinary team
  • Identify oral health considerations in the patient with oral cancer, from diagnosis and preparation for cancer therapy through survivorship and management of late complications
Recommended Audience: Assistant, Dentist, Hygienist